Immuno Oncology Assays Market

Immuno-oncology is emerging as a novel approach to cancer treatment through the stimulation of the body's own immune system. It is a formidable weapon against cancer as it has the ability to harness the body's natural defenses against infection. It is method that tap into the patient's own immune system to detect and destroy cancer cells. Immuno-oncology is one of the most promising areas of research in the world of anti-cancer therapeutics.

Market Dynamics:

Increase in burden of cancer across the globe, rise in focus on the development of novel cancer treatments, increase in research and development (R&D) activities, and growing significance of immuno-oncology are some major factors expected to drive growth of the global immuno-oncology assays market over the forecast period.

For instance, in April 2021, Roche announced the launch of its Elecsys Anti-p53 immunoassay to boost in vitro quantitative determination of anti-p53 antibodies to help diagnose throat, bowel, and breast cancer. Moreover, in April 2019, Roche Diagnostics announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for identification of human epidermal growth factor receptor 2 (HER2) biomarker in breast and gastric cancers.

Key features of the study:

• This report provides in-depth analysis of the global immuno-oncology assays market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global immuno-oncology assays market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Charles River, Roche, llumina, and Agilent Technologies, Inc., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global immuno-oncology assays market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology assays market.

Detailed Segmentation:

• Global Immuno-Oncology Assays Market By Product:
  • Consumables
  • Software
• Global Immuno-Oncology Assays Market By Technology:
  • Immunoassay
  • PCR
  • NGS
  • Flow Cytometry
  • Others
• Global Immuno-Oncology Assays Market By Indication:
  • Colorectal Cancer
  • Lung Cancer
  • Melanoma
  • Bladder Cancer
  • Others
• Global Immuno-Oncology Assays Market By Application:
  • Clinical Diagnostics
  • Research and Development
• Global Immuno-Oncology Assays Market By Region:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
• Company Profiles:
  • Charles River
  • Roche
  • Llumina
  • Agilent Technologies, Inc.